These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1201 related articles for article (PubMed ID: 18590786)

  • 1. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum.
    Healer J; Murphy V; Hodder AN; Masciantonio R; Gemmill AW; Anders RF; Cowman AF; Batchelor A
    Mol Microbiol; 2004 Apr; 52(1):159-68. PubMed ID: 15049818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
    Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
    Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protective antibody response to recombinant fragments of Plasmodium falciparum apical membrane antigen 1].
    Li X; Xue CF; Liu ZX; Wang XF; Ding J; Lei JC; Zhen RF
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2003; 21(2):80-3. PubMed ID: 12884614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
    Teo WH; Nurul AA; Norazmi MN
    Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
    Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
    Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism in msp-2, ama-1 and csp genes in Plasmodium falciparum field isolates from north and north-western India.
    Farooq U; Malla N; Dubey ML
    J Vector Borne Dis; 2009 Jun; 46(2):109-16. PubMed ID: 19502690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
    Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic diversity and natural selection at the domain I of apical membrane antigen-1 (AMA-1) of Plasmodium falciparum in isolates from Iran.
    Mardani A; Keshavarz H; Heidari A; Hajjaran H; Raeisi A; Khorramizadeh MR
    Exp Parasitol; 2012 Apr; 130(4):456-62. PubMed ID: 22306282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.
    Cortés A; Mellombo M; Masciantonio R; Murphy VJ; Reeder JC; Anders RF
    Infect Immun; 2005 Jan; 73(1):422-30. PubMed ID: 15618180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum: genetic polymorphism in apical membrane antigen-1 gene from Indian isolates.
    Rajesh V; Singamsetti VK; Vidya S; Gowrishankar M; Elamaran M; Tripathi J; Radhika NB; Kochar D; Ranjan A; Roy SK; Das A
    Exp Parasitol; 2008 May; 119(1):144-51. PubMed ID: 18343371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
    Moorthy SA; Yasawardena SG; Ramasamy R
    Vaccine; 2009 Aug; 27(36):4947-52. PubMed ID: 19545652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
    Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
    J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.